<DOC>
	<DOC>NCT01349673</DOC>
	<brief_summary>The purpose of this study is to evaluate safety and tolerability of cyclically dosed rectal budesonide foam in subjects with active ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS).</brief_summary>
	<brief_title>The Safety and Tolerability of Budesonide Foam in Subjects With Active Ulcerative Proctitis or Proctosigmoiditis</brief_title>
	<detailed_description>This is a Phase 3, multicenter, open label study in subjects who have participated previously in a Salix-sponsored budesonide rectal foam study for the treatment of ulcerative proctitis or proctosigmoiditis. Approximately 300 subjects will be enrolled into the study and receive budesonide foam cyclically for 6 weeks (BID for 2 weeks and QD for 4 weeks) each time they have an ulcerative proctitis or proctosigmoiditis flare. The study will continue until regulatory approval of budesonide foam occurs, or the sponsor decides to terminate the study.</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Proctitis</mesh_term>
	<mesh_term>Proctocolitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Peripheral Nervous System Agents</mesh_term>
	<criteria>Male or nonpregnant, non breastfeeding females â‰¥ 18 years old. Subject has previously been diagnosed with active mild to moderate UP/UPS and is currently experiencing symptoms of active UP/UPS disease after having completed participation in Salix's BUCF3001 or BUCF3002 study. Willingness to undergo sigmoidoscopy. Active systemic, ocular or cutaneous infection (e.g., parasitic, fungal, amoebic, viral or bacterial disease). History of sclerosing cholangitis, cirrhosis, or hepatic impairment, including chronic hepatitis of any etiology. Subject has taken systemic, inhaled, oral, topical or rectal corticosteroids (other than budesonide rectal foam) within 7 days of starting a treatment cycle. Subject has taken ketoconazole and other potent CYP3A4 inhibitors within 7 days of starting a treatment cycle. Subjects who take diuretics with cardiac glycosides. Unstable significant cardiovascular, hepatic, renal, endocrine, neurologic or pulmonary disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Open-label</keyword>
	<keyword>Proctitis</keyword>
	<keyword>Proctosigmoiditis</keyword>
	<keyword>Ulcerative</keyword>
	<keyword>Salix</keyword>
	<keyword>Budesonide foam</keyword>
	<keyword>Budesonide</keyword>
	<keyword>Rectal</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Colitis</keyword>
	<keyword>UC</keyword>
	<keyword>UP</keyword>
	<keyword>UPS</keyword>
	<keyword>Additional relevant MeSH terms:</keyword>
	<keyword>Proctocolitis</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Colitis, Ulcerative</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Sigmoid Diseases</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>Bronchodilator Agents</keyword>
	<keyword>Autonomic Agents</keyword>
	<keyword>Peripheral Nervous System Agents</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Anti-Asthmatic Agents</keyword>
	<keyword>Respiratory System Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormones, Hormone Substitutes and Hormone Antagonists</keyword>
	<keyword>Anti-inflammatory Agents</keyword>
</DOC>